Health ❯Healthcare ❯Biotechnology

Gene Therapy

Duchenne Muscular Dystrophy Bluebird Bio Market Trends FDA Cholesterol Management Cardiovascular Disease Hemophilia A Clinical Trials

Sarepta Defies FDA Order to Halt Elevidys After Third Patient Death

The FDA paused clinical trials after three liver-failure deaths linked to the Duchenne gene therapy.

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins

Sarepta Halts Elevidys Shipments for Non-Ambulatory Patients After Second Fatal Liver Failure

Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial

First Death Reported from Sarepta's Duchenne Gene Therapy Raises Safety Concerns

Pfizer Ends Hemophilia Gene Therapy Partnership With Sangamo, Sending Stock Plummeting